FDA has extended its goal for an orphan drug designation decision, placing more pressure on sponsors to ensure requests contain no problems from the start.
Orphan Designation Requests To Get Slower Reviews
FDA can't keep pace with requests, placing more pressure on sponsors to ensure submissions are complete.